Eporise 4000 Injection contains Recombinant Human Erythropoietin Alfa at a concentration of 4000 IU/ml, a glycoprotein hormone that stimulates erythropoiesis, the production of red blood cells, by acting on erythroid progenitor cells in the bone marrow. It is indicated for the treatment of anemia associated with chronic kidney disease (CKD), including patients on dialysis and those not on dialysis, as well as anemia due to chemotherapy in cancer patients, and anemia in certain other conditions such as zidovudine-treated HIV-infected patients. Eporise 4000 Injection is administered via subcutaneous or intravenous routes under medical supervision, with dosage individualized based on the patient's hemoglobin levels, clinical response, and underlying condition. The use of erythropoietin alfa reduces the need for blood transfusions, thereby minimizing transfusion-related risks. It is essential to monitor hemoglobin levels regularly to avoid excessive erythropoiesis, which may increase the risk of hypertension, thromboembolic events, and cardiovascular complications. Contraindications include uncontrolled hypertension and known hypersensitivity to the active substance or excipients. Eporise 4000 Injection should be used cautiously in patients with a history of seizures or cardiovascular disease, and it is recommended to follow established guidelines for dosing and monitoring to ensure safety and efficacy.